You searched for "studies"

1541 results found

Renewed momentum in ocular gene and cell therapy, broadening application to chronic disease

Gene and cell therapies offer the prospect of ground-breaking new avenues for the treatment of diseases, reflected in a renewed explosion of interest and investment in retinal gene therapy. Rod McNeil reports recent clinical trial readouts across a diverse range...

Could Twitter boost the impact of ophthalmic journal articles?

*Equally contributing co-first authors. The authors investigate the link between ‘tweets’ and citations for 155 articles from five key ophthalmology journals. Social media’s impact on our lives has been significant, allowing easy discussion of topics worldwide. An increasing number of...

What’s new in glaucoma? Clinical trials drive practice changes, surgical advancements gather pace

Rod McNeil reviews the latest developments in the treatment of glaucoma in the UK. Primary open-angle glaucoma (POAG), which accounts for over two-thirds of all glaucoma cases, has an estimated UK prevalence in 2017 of approximately 2% of people over...

A life outside ophthalmology

Lloyd Paul Aiello. It was an absolute privilege to speak to Lloyd Paul Aiello, Professor of Ophthalmology, Harvard Medical School, and Vice President of Ophthalmology and Director, Beetham Eye Institute, Joslin Diabetes Center, USA. Prof Aiello is a third-generation ophthalmologist,...

Eyes on Tomorrow podcast: “Desert Island Discs for ophthalmologists”

What happens when an ophthalmologist and optometrist get chatting in a pub, over a couple of pints of Guinness, about how they could create something educational and entertaining for ophthalmologists and optometrists? The answer is the Eyes on Tomorrow podcast....

Santorini sunlight!

In the heart of London, Hollywood icon Keanu Reeves attended his inspiring book launch event held at the Royal Festival Hall, later followed by a book signing at Waterstones in Piccadilly, London. Ticket holders included ladies from the Literacy Ladies...

Conference Preview: UKISCRS, UKISOP and YOP 2025

London’s calling, and we will be rejoining the United Kingdom & Ireland Society of Cataract & Refractive Surgeons (UKISCRS), the Young Ophthalmologists Programme (YOP), and United Kingdom & Ireland Society of Ophthalmic Practitioners (UKISOP) between 12–14 November. The former will...

Time is vision in central retinal artery occlusion

Central retinal artery occlusion (CRAO) is a rare but devastating vascular episode that can have severe impact on vision. Treatment is very time-limited and needs to be initiated very quickly to salvage any vision. The majority of patients present to...

Adaptive optics imaging: resolving single cells in the living eye

The human retina is unique in the central nervous system (CNS) in that it can be directly visualised non-invasively. Technological advances of several imaging modalities, including optical coherence tomography (OCT), multichannel scanning laser ophthalmoscopy (SLO) and fundus photography, have afforded...

Overcoming sight impairment for the Race Across the World!

RNIB’s Tricia travels the world and takes her message that "sight loss doesn’t stop you doing anything" to BBC One.

RNIB and British Blind Sport join forces to tackle the disparity of physical activity amongst blind and partially sighted people

The UK’s leading sight loss charity, Royal National Institute of Blind People (RNIB) and British Blind Sport have joined forces to launch the See Sport Differently campaign, which aims to promote accessible sports and breakdown barriers faced by blind and partially sighted people who want to get active.

‘Class of 2024’ graduate from SpaMedica’s STEPS programme as ophthalmic surgeon celebrates first year teaching trainees to complete over 500 cataract cases

As the latest ‘Class of 2024’ graduate from SpaMedica’s Training and Education Programme for Surgeons (STEPS), a brand-new cohort of surgical trainees will take up positions at SpaMedica hospitals nationwide. Representing the next generation of ophthalmologists, they will benefit from...